Mystic Pharmaceuticals
Developer of non‑invasive drug and biologic delivery device platforms and unit‑dose primary container systems for ophthalmic, intranasal (systemic), nose‑to‑brain, sublingual/buccal, otic and animal care applications. Provides device design, unit‑dose blister packaging, analytical characterization, fill/finish engineering, preclinical/clinical supply support and commercial scale‑up services for pharmaceutical, biotech and public‑health countermeasure applications.
Industries
Nr. of Employees
small (1-50)
Mystic Pharmaceuticals
PO Box 342216, Austin, TX 78734, United States
Products
Platform for liquid delivery and unit‑dose blister packaging
Integrated liquid delivery platform composed of unit‑dose blisters with embedded micro‑nozzles and matching handheld dispensers, configurable for ophthalmic, intranasal, nose‑to‑brain, sublingual and animal care applications.
Platform for powder delivery and reconstitution
Integrated powder delivery platform supporting dry powder, reconstituted powder‑to‑liquid and liquid/liquid recombination applications with active powder aerosolization and unit‑dose blister packaging.
Platform for liquid delivery and unit‑dose blister packaging
Integrated liquid delivery platform composed of unit‑dose blisters with embedded micro‑nozzles and matching handheld dispensers, configurable for ophthalmic, intranasal, nose‑to‑brain, sublingual and animal care applications.
Platform for powder delivery and reconstitution
Integrated powder delivery platform supporting dry powder, reconstituted powder‑to‑liquid and liquid/liquid recombination applications with active powder aerosolization and unit‑dose blister packaging.
Services
Dispense characterization (laser diffraction), plume morphology (high‑speed video), aerodynamic deposition testing (cascade impactor and nasal cast), delivered dose uniformity/consistency, emitted dose (shot weight), size‑exclusion chromatography, device force to actuate, and fluidic properties analysis.
Prototype configuration and supply, primary container/dispenser configuration and optimization, analytical testing, process engineering for fill operations, preclinical and clinical supply support, and regulatory documentation (DMF).
Commercial technology transfer, commercial scale‑up, commercial supply through partners, capital equipment supply and siting, and technology licensing.
Dispense characterization (laser diffraction), plume morphology (high‑speed video), aerodynamic deposition testing (cascade impactor and nasal cast), delivered dose uniformity/consistency, emitted dose (shot weight), size‑exclusion chromatography, device force to actuate, and fluidic properties analysis.
Prototype configuration and supply, primary container/dispenser configuration and optimization, analytical testing, process engineering for fill operations, preclinical and clinical supply support, and regulatory documentation (DMF).
Commercial technology transfer, commercial scale‑up, commercial supply through partners, capital equipment supply and siting, and technology licensing.
Expertise Areas
- Non‑invasive drug delivery device development
- Unit‑dose blister packaging and primary container materials
- Fill/finish manufacturing and commercial scale‑up
- Analytical characterization of aerosols and sprays
Key Technologies
- Form‑Fill‑Seal (FFS) unit‑dose blister manufacturing
- Multi‑layer laminate primary containers with high barrier properties
- Micro‑molded medical‑grade polymer micro‑nozzles
- Laser diffraction droplet/particle sizing
News & Updates
Announcement of issued patents (U.S. and EU) for cartridge and hand‑operated administration devices strengthening the company's delivery platform portfolio for nasal, ophthalmic and sublingual routes.
Launch announcement for cartridge‑reloadable and single‑use dry powder nasal delivery devices intended for systemic and nose‑to‑brain administration.
Announcement of participation in a U.S. government rapid response partnership to support scalable distribution of vaccines and medical countermeasures.
Local press release describing company relocation to Cedar Park, Texas and engagement with the local life‑sciences community.
Patents issued covering cartridge devices and hand‑operated administration devices for nasal, ophthalmic and sublingual drug delivery (U.S. Patent and EU Patent cited in press release).
Commercial launch announcements for cartridge‑reloadable and single‑use dry powder nasal delivery systems intended for drugs and biologics.
Announcement of issued patents (U.S. and EU) for cartridge and hand‑operated administration devices strengthening the company's delivery platform portfolio for nasal, ophthalmic and sublingual routes.
Launch announcement for cartridge‑reloadable and single‑use dry powder nasal delivery devices intended for systemic and nose‑to‑brain administration.
Announcement of participation in a U.S. government rapid response partnership to support scalable distribution of vaccines and medical countermeasures.
Local press release describing company relocation to Cedar Park, Texas and engagement with the local life‑sciences community.
Patents issued covering cartridge devices and hand‑operated administration devices for nasal, ophthalmic and sublingual drug delivery (U.S. Patent and EU Patent cited in press release).
Commercial launch announcements for cartridge‑reloadable and single‑use dry powder nasal delivery systems intended for drugs and biologics.